As reported, the immunization of wild-type mice with full-length tau recombinant protein in combination with CFA and pertussis toxin (PT) leads to tauopathy-like abnormalities and neurological deficits17, which are presumably related to the use of full-length human tau protein differing from the mouse sequence or the use of strong adjuvants such as CFA and PT that induce a strong cytotoxic T-cell response. The gene discussed is F2; the disease is tauopathy.